摘要
Future Medicinal ChemistryVol. 14, No. 3 EditorialMolecular glues targeting protein degradation pathways for drug discoveryChangyu Ren, Xiaohong Gan, Houfeng Zhou, Jinqi Li & Jifa ZhangChangyu RenDepartment of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaSearch for more papers by this author, Xiaohong GanDepartment of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaSearch for more papers by this author, Houfeng ZhouDepartment of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaSearch for more papers by this author, Jinqi Li*Author for correspondence: E-mail Address: lijinqi2002@126.comDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan, 610072, ChinaSearch for more papers by this author & Jifa Zhang **Author for correspondence: E-mail Address: zjf298257@163.comhttps://orcid.org/0000-0001-8618-9200Department of Pharmacy, Chengdu Fifth People's Hospital, Chengdu, Sichuan, 611130, ChinaState Key Laboratory of Biotherapy and Cancer Center, National Clinical Research Center for Geriatrics, West China Hospital of Sichuan University, Chengdu, Sichuan, 610041, ChinaSearch for more papers by this authorPublished Online:15 Nov 2021https://doi.org/10.4155/fmc-2021-0229AboutSectionsView ArticleView Full TextPDF/EPUB ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareShare onFacebookTwitterLinkedInReddit View articleKeywords: degraded proteinsdrug discoverymolecular gluesnon-drug targetsReferences1. Platis D, Sotriffer CA, Clonis Y et al. Lock-and-key motif as a concept for designing affinity adsorbents for protein purification. J. Chromatogr. A 1128(1–2), 138–151 (2006).Crossref, Medline, CAS, Google Scholar2. Liu CL, Zhang R, Zhang WZ et al. “Dual-key-and-lock” ruthenium complex probe for lysosomal formaldehyde in cancer cells and tumors. J. Am. Chem. Soc. 141(21), 8462–8472 (2019).Crossref, Medline, CAS, Google Scholar3. Pei JP, Wang G, Feng L et al. Targeting lysosomal degradation pathways: new strategies and techniques for drug discovery. J. Med. Chem. 64(7), 3493–3507 (2021).Crossref, Medline, CAS, Google Scholar4. Chamberlain PP, Hamann LG. Development of targeted protein degradation therapeutics. Nat. Chem. Biol. 15(10), 937–944 (2019).Crossref, Medline, CAS, Google Scholar5. Wang Y, Jiang X, Feng F et al. Degradation of proteins by PROTACs and other strategies. Acta Pharm. Sin. B 10(2), 207–238 (2020).Crossref, Medline, CAS, Google Scholar6. Zhang JF, Ouyang L. Proteolysis-targeting chimeras in breast cancer therapy. Future. Med. Chem. 12(24), 2175–2177 (2020).Link, CAS, Google Scholar7. Schreiber SL. The rise of molecular glues. Cell 184, 3–9 (2021).Crossref, Medline, CAS, Google Scholar8. Baek K, Schulman BA. Molecular glue concept solidifies. Nat. Chem. Biol. 16, 2–3 (2020).Crossref, Medline, CAS, Google Scholar9. Tian C, Burgess K. PROTAC compatibilities, degrading cell-surface receptors, and the sticky problem of finding a molecular glue. ChemMedChem 16(2), 316–318 (2021).Crossref, Medline, CAS, Google Scholar10. Chamberlain PP, Cathers BE. Cereblon modulators: low molecular weight inducers of protein degradation. Drug Discov. Today Technol. 31, 29–34 (2019).Crossref, Medline, Google Scholar11. Matyskiela ME, Lu G, Ito T et al. A novel cereblon modulator recruits GSPT1 to the CRL4(CRBN) ubiquitin ligase. Nature 535, 252–257 (2016).Crossref, Medline, CAS, Google Scholar12. Słabicki M, Kozicka Z, Petzold G et al. The CDK inhibitor CR8 acts as a molecular glue degrader that depletes cyclin K. Nature 585(7824), 293–297 (2020).Crossref, Medline, CAS, Google Scholar13. Isobe Y, Okumura M, McGregor ML et al. Manumycin polyketides act as molecular glues between UBR7 and P53. Nat. Chem. Biol. 16(11), 1189–1198 (2020).Crossref, Medline, CAS, Google Scholar14. Yang Y, Sun Y, Wang J et al. Allele-selective lowering of mutant HTT protein by HTT-LC3 linker compounds. Nature 575, 203–209 (2019).Crossref, Medline, Google Scholar15. Lin X, Xiang H, Luo G. Targeting estrogen receptor alpha for degradation with PROTACs: a promising approach to overcome endocrine resistance. Eur. J. Med. Chem. 206, 112689 (2020).Crossref, Medline, CAS, Google Scholar16. Maniaci C, Ciulli A. Bifunctional chemical probes inducing protein–protein interactions. Curr. Opin. Chem. Biol. 52, 145–156 (2019).Crossref, Medline, CAS, Google Scholar17. Dong GQ, Ding Y, He SP. Molecular glues for targeted protein degradation: from serendipity to rational discovery. J. Med. Chem. 64(15), 10606–10620 (2021).Crossref, Medline, CAS, Google Scholar18. Zou Y, Ma D, Wang Y. The PROTAC technology in drug development. Cell Biochem. Funct. 37, 21–30 (2019).Crossref, Medline, CAS, Google ScholarFiguresReferencesRelatedDetails Vol. 14, No. 3 Follow us on social media for the latest updates Metrics Downloaded 237 times History Received 10 August 2021 Accepted 27 October 2021 Published online 15 November 2021 Published in print February 2022 Information© 2021 Newlands PressKeywordsdegraded proteinsdrug discoverymolecular gluesnon-drug targetsFinancial & competing interests disclosureThe authors thank the National Natural Science Foundation of China (81903502), China Postdoctoral Science Foundation (2020M673268), Health Commission of Sichuan Province (20PJ002) and the Xinglin Foundation of Chengdu University of TCM (YYZX2021043). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.No writing assistance was utilized in the production of this manuscript.PDF download